Tuhura Biosciences, Inc/nv Form 4 insider transactions

TuHURA Biosciences CEO James A. Bianco reported gifting 150,000 shares of common stock to his adult sons.

TuHURA Biosciences' Chief Financial Officer, Dan Dearborn, was granted 273,696 stock options with an exercise price of $0.73, vesting over three years.

TuHURA Biosciences, Inc. CEO James A. Bianco received a supplemental grant of 610,332 stock options with an exercise price of $0.73.

TuHURA Biosciences' Chief Financial Officer, Dan Dearborn, was granted 1,531,367 stock options with an exercise price of $1.02, vesting over three years.

TuHURA Biosciences CEO James A. Bianco was granted 3,414,891 stock options with an exercise price of $1.02, vesting over three years.

TuHURA Biosciences and Kineta, Inc. stockholders have overwhelmingly approved all merger-related proposals, including an increase in TuHURA's authorized shares and reincorporation to Delaware, clearing a significant hurdle for the companies' anticipated merger.

TuHURA Biosciences, Inc. has entered into a definitive securities purchase agreement for a private placement totaling approximately $12.6 million, alongside an additional $3.0 million from prior warrant exercises, to fund its strategic merger with Kineta, Inc. and advance its oncology pipeline.

TuHURA Biosciences, Inc. announced a definitive agreement for a $12.5 million private placement and an additional $3.0 million from warrant exercises, aimed at funding its Phase 3 trial, Kineta merger, and pipeline advancement.

TuHURA Biosciences announced its Q1 2025 financial results and provided a corporate update, highlighting the anticipated initiation of a Phase 3 trial for IFx-Hu2.0 and progress towards acquiring Kineta, Inc.

TuHURA Biosciences will present a company overview at the H.C. Wainwright BioConnect Conference, highlighting its Phase 3 program and the acquisition of Kineta, including its VISTA inhibiting monoclonal antibody program.

TuHURA Biosciences amends its merger agreement with Kineta, extending the end date to June 30, 2025, and finalizes a separation agreement with its former Chief Scientific Officer, Dennis Yamashita.

TuHURA Biosciences has commenced a Phase 1b/2a clinical trial to evaluate the safety and feasibility of IFx-Hu2.0 in combination with Keytruda for patients with metastatic Merkel Cell Carcinoma of Unknown Primary Origin.

TuHURA Biosciences and Kineta presented updated results from clinical trials of KVA12123 and IFx-Hu2.0, showing potential in treating advanced melanoma and other cancers after failure of anti-PD-1 therapy.

TuHURA Biosciences announces that abstracts highlighting Kineta Inc.'s KVA12123 antibody and Moffitt Cancer Center scientists' examination of IFx-Hu2.0 therapy mechanisms have been selected for poster presentation at the AACR Annual Meeting 2025.

TuHURA Biosciences announces its 2024 financial results, a corporate update focusing on its Phase 3 trial for IFx-2.0, and the planned acquisition of Kineta, Inc.

Director Craig Tendler reports acquisition of options in TuHURA Biosciences, Inc.

Director Robert E. Hoffman of TuHURA Biosciences, Inc. was granted 51,275 stock options on January 2, 2025, as part of the company's Non-Employee Director Compensation Program.

Director James Manuso acquired options for 59,590 shares of TuHURA Biosciences common stock as part of the company's Non-Employee Director Compensation Program.

Director Alan List reports receiving an option grant for 51,275 shares of TuHURA Biosciences common stock.

Director George Ng acquired 51,275 options in TuHURA Biosciences as part of the company's Non-Employee Director Compensation Program.

TuHURA Biosciences has entered into a definitive agreement to acquire Kineta, adding a Phase 2 novel checkpoint inhibitor to its pipeline.

TuHURA Biosciences CEO, James A. Bianco, was granted 1,065,990 stock options on November 12, 2024, which vest over three years.

TuHURA Biosciences' Chief Financial Officer, Dan Dearborn, acquired 489,848 stock options on November 12, 2024, which vest over three years.

Dennis Yamashita, Chief Scientific Officer of Kintara Therapeutics (now TuHURA Biosciences), reports acquisition of options following the merger with TuHURA Biosciences.

Director George Ng reports acquisition of options in Kintara Therapeutics (now TuHURA Biosciences) following the completion of a merger with TuHURA Biosciences on October 18, 2024.

Director Alan List reports the acquisition of derivative securities in Kintara Therapeutics (now TuHURA Biosciences) following the completion of a merger with TuHURA Biosciences.

James S. Manuso, a director of Kintara Therapeutics (now TuHURA Biosciences), acquired options to purchase common stock following the completion of a merger with TuHURA Biosciences on October 18, 2024.

CEO James Bianco reports acquisition of common stock and options in Kintara Therapeutics following the merger with TuHURA Biosciences.

Dan Dearborn, CFO of Kintara Therapeutics (now TuHURA Biosciences), reports the acquisition of options as a result of the merger with TuHURA Biosciences.

Kintara Therapeutics' stockholders approved proposals necessary for the merger with TuHURA Biosciences, including the issuance of merger shares, a reverse stock split, and the adoption of TuHURA's equity incentive plan, but did not approve the Charter Proposal or the Reincorporation Proposal.